BLAINJECTIONINJECTABLE
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FILKRI (filgrastim-laha) by Accord Biopharma is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Approved for neutropenia, breast cancer. First approved in 2026.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILKRI (filgrastim-laha) is a biosimilar granulocyte colony-stimulating factor (G-CSF) approved January 2026 by Accord Biopharma. It stimulates neutrophil production by binding to cell surface receptors on hematopoietic cells, promoting proliferation and differentiation. Indicated for chemotherapy-induced neutropenia and breast cancer patients receiving myelosuppressive therapy.
Growth
Early-stage launch in a mature supportive care market with moderate competitive pressure (30/100); biosimilar entry implies smaller commercial footprint than reference product.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Indications (2)
Worked on FILKRI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.